• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1277996 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type0 e5 B2 e% X4 \7 \  W4 S9 N
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 * c& S% T. j7 `/ E# \4 y
+ Author Affiliations7 S# s$ W9 }% _6 Y- Q
% [/ d0 k6 u6 c3 y
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan . G6 s# \$ u# y
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ) M8 j1 J+ z8 @
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
8 h9 r3 y6 g! s$ t; A4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan + ~0 U6 t( j6 [8 ^
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
* R1 a8 t! m4 V  d6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
& D! q$ @# q6 ~6 m+ {& [" m7Kinki University School of Medicine, Osaka 589-8511, Japan ( P: Z4 h( c2 C2 ?5 O3 k) ^
8Izumi Municipal Hospital, Osaka 594-0071, Japan
; A' h1 d* u# P9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan   e& l* t) T8 U/ U4 F
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- \2 G. o' X- V) u# t. ~! H! pAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , k: K+ e! j4 n1 q

/ {. A9 H$ [4 z5 K( }# n
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
8 X: Z# x. D- \
. }$ K; k6 r* a0 h9 ]Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 4 C+ ^! d6 ~& _7 L7 Y
" J- e' f2 b3 N8 f; A* S' s3 \2 P3 [) ~
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
, L3 O5 h0 l  p2 T2 \' M3 V9 s2 r  V7 Y% J
Published online on: Thursday, December 1, 2011 ( x! z( m8 G8 c
$ f6 V, u9 s+ T- p. p# D# }
Doi: 10.3892/ol.2011.507
/ B/ P2 s- f; T* @; G# T+ f& F
1 L, w- a6 Z5 P& m$ P; wPages: 405-410 . T& t6 f2 [) g- b, K: b9 b
0 \7 V: S  A3 M% A4 j# D4 z
Abstract:3 F/ |: A* R7 }9 z4 S7 P
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
. ~& F! v- c9 X% I7 _
. [8 \. @; ?& H6 a
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. j2 m& D' o/ v. k
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
: V$ K8 _3 }3 G5 M& @: C5 H+ Author Affiliations$ b7 C2 W  T+ M9 T1 B" T
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu , R( E3 p) ~& p" o1 `( o5 r5 G4 ^
2Department of Thoracic Surgery, Kyoto University, Kyoto 2 Q3 `" ^2 W# G% N" X6 r
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan # D! X" R$ Z* x1 a9 X
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
: g* T1 d' C9 y# h- tReceived September 3, 2010.
" K: X6 B% c5 a9 V0 a, L) MRevision received November 11, 2010. " p# h4 e5 K, a) W, |8 }; D% m
Accepted November 17, 2010. $ X. `' @- @0 j, V% l/ Y
Abstract, p4 {* _' T+ b8 f+ R% h5 `4 T7 \* ]
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. . C3 m; C* w3 V6 [
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. - B6 Q/ y# h9 s+ N% u' f% J
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
4 b5 M! B2 H0 u7 T; j' j$ v) dConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
2 G/ q1 {" `; \0 e
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。/ s2 r+ ^- d( H1 t( m7 e, F$ R/ F
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?+ t1 U# @* G5 E* h; @
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
. F5 C$ c( _0 L& m3 U) P; H  l/ L$ Mhttp://clinicaltrials.gov/ct2/show/NCT01523587$ k2 G. j! q- b0 Z% L5 t, S+ z

  Z1 Q  x7 Y- p0 F0 gBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
) \/ k3 d. h# O2 W: O# d$ khttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 ( J6 j% r/ b, y/ q: v* M3 V& |3 K
  p8 v3 G2 f  v" n4 q* E" R2 y
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。% u$ f9 p* X9 y/ \
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 $ j1 U( H  Q% u) Y" O
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。, y% G# R) A% p# L! ~0 ~
至今为止,未出 ...

& v. \# r, v2 R! [5 s! ~没有副作用是第一追求,效果显著是第二追求。: \6 ?5 }- p6 n) J
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表